Page last updated: 2024-12-10
a-007
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3089902 |
| CHEMBL ID | 307697 |
| SCHEMBL ID | 18821 |
| SCHEMBL ID | 13657372 |
| SCHEMBL ID | 13657375 |
| MeSH ID | M0256742 |
Synonyms (32)
| Synonym |
|---|
| a-007 |
| sivifene |
| 4,4'-dihydroxybenzophenone-2,4-dinitrophenyl-hydrazone |
| a007 , |
| a 007 |
| 4,4'-dihydroxybenzophenone 2,4-dinitrophenylhydrazone |
| CBDIVE_002876 |
| AKOS000528225 |
| CHEMBL307697 |
| D09380 |
| sivifene (usan/inn) |
| 2675-35-6 |
| 4-[[2-(2,4-dinitrophenyl)hydrazinyl]-(4-hydroxyphenyl)methylidene]cyclohexa-2,5-dien-1-one |
| sivifene [usan:inn] |
| methanone, bis(4-hydroxyphenyl)-, (2,4-dinitrophenyl)hydrazone |
| unii-xav05295i5 |
| xav05295i5 , |
| sivifene [usan] |
| 4,4'-((2-(2,4-dinitrophenyl)hydrazinylidene)methylene)diphenol |
| sivifene [who-dd] |
| sivifene [inn] |
| SCHEMBL18821 |
| SCHEMBL13657372 |
| SCHEMBL13657375 |
| AKOS026676522 |
| 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone |
| 4-[n-(2,4-dinitroanilino)-c-(4-hydroxyphenyl)carbonimidoyl]phenol |
| cid 5717660 |
| bis(4-hydroxyphenyl)methanone (2,4-dinitrophenyl)hydrazone |
| DB05686 |
| Q27293750 |
| DTXSID30949554 |
Research Excerpts
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " A relative oral bioavailability factor of 2% was calculated for rats and monkeys for plasma A-007." | ( Comparative preclinical toxicology and pharmacology of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in vitro and in rodents and primates. Fan, D; Harrison, TJ; Morgan, LR; Ratterree, M; Rodgers, AH; Sartin, BW; Soike, K, ) | 0.56 |
| " Oral bioavailability data suggests that this is not an efficient mode of drug administration and availability diminishes as one progresses from rodents to primates (relative oral bioavailability 2%); thus suggesting an alternative form of drug delivery is required in higher species." | ( Relative bioavailability of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) in rats and monkeys. Morgan, LR; Ratteree, M; Rodgers, AH; Soike, K; Subramasnian, S, 1996) | 0.52 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (26)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID219155 | In vitro cytotoxicity in estrogen receptor and progesterone receptor negative Human breast tumor cells; (5+/-2, 0.2+/-0.3) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID82567 | Cytotoxicity in HH T-lymphocytic leukemia cells | 2002 | Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23 | Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers. |
| AID90629 | Tested for anticancer activity against human melanoma | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts. |
| AID90136 | Tested for anticancer activity against human breast cancer | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts. |
| AID88857 | Tested for anticancer activity against human ovarian cancer | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts. |
| AID68950 | In vitro cytotoxicity in FDCP-1 cell line | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID42937 | Binding Intensity against CD45+ HH-leukemic cells at 5 ug/mL | 2002 | Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23 | Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers. |
| AID44521 | Binding Intensity against CD11C+ HH-leukemic cells at 5 ug/mL | 2002 | Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23 | Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers. |
| AID219888 | In vitro cytotoxicity in Human colon tumor cells; (>12+/-4, >12+/-5) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID94688 | In vitro cytotoxicity in KM 12L4 cell line; Not available | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID94683 | In vitro cytotoxicity in KM 12 C cell line; Not available | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID219156 | In vitro cytotoxicity in estrogen receptor negative progesterone receptor positive Human breast tumor cells; (3+/-2, 0.4+/-0.1) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID222164 | In vitro cytotoxicity in Human melanoma tumor cells; (5+/-4, >10) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID95467 | In vitro cytotoxicity in K 1735 M2 cell line; Not available | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID157392 | Tested against normal human peripheral blood dendritic cells, expressed as IC50 | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts. |
| AID94684 | In vitro cytotoxicity in KM 12 SM cell line | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID219157 | In vitro cytotoxicity in estrogen receptor positive progesterone receptor negative Human breast tumor cells; (>5, 0.5) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID105051 | In vitro cytotoxicity in MDA-MB-435/lung met cell line; Not available | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID42618 | Binding Intensity against CD4+ HH-leukemic cells at 5 ug/mL. | 2002 | Bioorganic & medicinal chemistry letters, Dec-02, Volume: 12, Issue:23 | Anticancer activity for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) analogues and their abilities to interact with lymphoendothelial cell surface markers. |
| AID223650 | In vitro cytotoxicity in Human ovary tumor cells; (3+/-3, 4.2+/-4) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID38019 | In vitro cytotoxicity in B 16 F10 cell line | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID146558 | Tested for anticancer activity against human lung cancer (NSCLC) | 2001 | Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16 | Anticancer properties for 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007)/3,7-diaminophenothiazin-5-ium double salts. |
| AID101979 | In vitro cytotoxicity in MDA-MB-435 cell line | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID221337 | In vitro cytotoxicity in Human lung tumor cells; (5+/-5, 6+/-5) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID222038 | In vitro cytotoxicity in estrogen receptor and progesterone receptor positive Human breast tumor cells; (2.5+/-0.9, 0.5+/-1) | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| AID200306 | In vitro cytotoxicity in SN 12 PM6 cell line | 2003 | Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21 | Design, synthesis, and anticancer properties of 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and analogues. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 76.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (76.67) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (7.69%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||